Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells

8Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Background: Programmed cell death-ligand 1 (PD-L1) protein expression is one of the most extensively studied biomarkers in patients with non-small cell lung cancer (NSCLC). However, there is scarce information regarding its association with distinct adenocarcinoma subtypes. This study evaluated the frequency of PD-L1 expression according to the IASLC/ATS/ERS classification and other relevant histological and clinical features. Patients and Methods: PD-L1 expression was assessed by immunohistochemistry (IHC). According to its positivity in tumor cells membrane, we stratified patients in three different tumor proportions score (TPS) cut-off points: a) <1% (negative), b) between 1 and 49%, and c) ≥50%; afterward, we analyzed the association among PD-L1 expression and lung adenocarcinoma (LADC) predominant subtypes, as well as other clinical features. As an exploratory outcome we evaluated if a PD-L1 TPS score ≥15% was useful as a biomarker for determining survival. Results: A total of 240 patients were included to our final analysis. Median age at diagnosis was 65 years (range 23–94 years). A PD-L1 TPS ≥1% was observed in 52.5% of the entire cohort; regarding specific predominant histological patterns, a PD-L1 TPS ≥1 was documented in 31.2% of patients with predominant-lepidic pattern, 46.2% of patients with predominant-acinar pattern, 42.8% of patients with a predominant-papillary pattern, and 68.7% of patients with predominant-solid pattern (p = 0.002). On the other hand, proportion of tumors with PD-L1 TPS ≥50% was not significantly different among adenocarcinoma subtypes. At the univariate survival analysis, a PD-L1 TPS cut-off value of ≥15% was associated with a worse PFS and OS. Conclusion: According to IASLC/ATS/ERS lung adenocarcinoma classification, the predominant-solid pattern is associated with a higher proportion of PD-L1 positive samples, no subtype was identified to be associated with a high (≥50%) TPS PD-L1.

References Powered by Scopus

Cancer statistics, 2019

17478Citations
N/AReaders
Get full text

The blockade of immune checkpoints in cancer immunotherapy

11042Citations
N/AReaders
Get full text

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

10554Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Modifying factors of PD-L1 expression on tumor cells in advanced non-small-cell lung cancer

5Citations
N/AReaders
Get full text

Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients

2Citations
N/AReaders
Get full text

Factors correlating the expression of PD-L1

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Cruz-Rico, G., Avilés-Salas, A., Popa-Navarro, X., Lara-Mejía, L., Catalán, R., Sánchez-Reyes, R., … Arrieta, O. (2021). Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells. Pathology and Oncology Research, 27. https://doi.org/10.3389/pore.2021.597499

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

63%

Researcher 3

38%

Readers' Discipline

Tooltip

Medicine and Dentistry 8

73%

Immunology and Microbiology 1

9%

Social Sciences 1

9%

Agricultural and Biological Sciences 1

9%

Save time finding and organizing research with Mendeley

Sign up for free